SEC Form 4 · accession 0001179110-18-002259
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harry J Leonhardt
Officer — SVP, GC and CCO
Period of report
Feb 14, 2018
Accepted (ET)
Feb 16, 2018 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $18.41 | Feb 14, 2018 | A | 54,780 | A | Feb 14, 2019 | Feb 14, 2028 | Common Stock | 54,780 | 54,780 | D |
| Restricted Stock UnitsF2 | $0.00 | Feb 14, 2018 | A | 31,234 | A | Feb 14, 2019 | — | Common Stock | 31,234 | 31,234 | D |
Explanation of responses
- F1This option vests one-fourth on such date and then 1/48th monthly thereafter.
- F2This award vests one-fourth on the first anniversary of the grant date then one-fourth on each anniversary date thereafter.